Azurity Pharmaceuticals, Inc. v. Aurobindo Pharma Limited
| Azurity Pharmaceuticals, Inc. |
| Aurobindo Pharma Limited |
| 1:2026cv00785 |
| July 1, 2026 |
| U.S. District Court for the District of Delaware |
| Gregory B Williams |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 1 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on July 23, 2026. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Pro Hac Vice Attorney Mark A. Hayden, Emily M. Shingle, Wendy L. Devine & Natalie J. Morgan for Azurity Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (slk) |
SO ORDERED, re #7 MOTION for Pro Hac Vice Appearance of Attorney Wendy L. Devine, Natalie J. Morgan, Emily M. Shingle, and Mark A. Hayden of Wilson Sonsini Goodrich & Rosati P.C. filed by Azurity Pharmaceuticals, Inc. Signed by Judge Gregory B. Williams on 7/14/2026. (lnb)
|
| Filing 8 Pro Hac Vice Fee - Credit Card Payment received for Wendy L. Devine, Natalie J. Morgan, Emily M. Shingle, and Mark A. Hayden. ( re #7 MOTION for Pro Hac Vice Appearance of Attorney Wendy L. Devine, Natalie J. Morgan, Emily M. Shingle, and Mark A. Hayden of Wilson Sonsini Goodrich & Rosati P.C. )( Payment of $ 200, receipt number ADEDC-5014487).(Palapura, Bindu) |
| Filing 7 MOTION for Pro Hac Vice Appearance of Attorney Wendy L. Devine, Natalie J. Morgan, Emily M. Shingle, and Mark A. Hayden of Wilson Sonsini Goodrich & Rosati P.C. - filed by Azurity Pharmaceuticals, Inc.. (Palapura, Bindu) |
| Filing 6 WAIVER OF SERVICE returned executed by Azurity Pharmaceuticals, Inc.: For Aurobindo Pharma Limited waiver sent on 7/8/2026, answer due 10/6/2026. (Moore, David) |
| Case Assigned to Judge Gregory B. Williams. Please include the initials of the Judge (GBW) after the case number on all documents filed. (alb) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent CutisPharma Intermediate Holdings, Inc. for Azurity Pharmaceuticals, Inc. - filed by Azurity Pharmaceuticals, Inc. (jfm) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 11,478,456 B2; US 11,529,333 B2; US 12,491,179 B2. (jfm) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 05/19/2026. Date of Expiration of Patent: 08/18/2038.Thirty Month Stay Deadline: 11/19/2028. (jfm) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jfm) |
| Filing 1 COMPLAINT for Patent Infringement against Aurobindo Pharma Limited (Filing fee $ 405, receipt number ADEDC-5005983) - filed by Azurity Pharmaceuticals, Inc. (Attachment(s) #1 Exhibits, A-C, #2 Civil Cover Sheet) (jfm). |
| No Summons Issued. (jfm) |
Access additional case information on PACER
Use the links below to access additional information about this case on the U.S. Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
